Loading
Life sciences · Journal article
Bioconjugate Chemistry · October 8, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Ultrasound-triggered site-specific molecular chemistry has emerged as a transformative strategy for cancer therapy, yet precise spatiotemporal control of their activity remains a critical bottleneck. Endogenous stimulus-responsive strategies are hampered by tumor heterogeneity, while exogenous physical triggers provide superior controllability. This article proposes that ultrasound-triggered site-specific chemistry, termed “acoustic programming”, offers a transformative solution. By integrating focused ultrasound deep-tissue penetration with molecular-level chemical control, acoustically programmable bioconjugates achieve deep-tissue, on-demand therapeutic activation. We survey recent advances in sono-labile linkers, ultrasound-triggered charge reversal, and sono-chemically activated prodrugs, and critically evaluate emerging proof-of-concept and in vivo validated applications in ultrasound-caged PROTACs, immunomodulators, and antibody-drug conjugates. This paradigm shift from “ultrasound-responsive materials” to “ultrasound-responsive molecules” positions acoustic programming as a core platform technology for next-generation precision oncology.